Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Other Non-Current Liabilities (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Other Non-Current Liabilities for 11 consecutive years, with $117000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Liabilities fell 99.01% year-over-year to $117000.0, compared with a TTM value of $117000.0 through Sep 2025, down 99.01%, and an annual FY2024 reading of $350000.0, down 93.69% over the prior year.
  • Other Non-Current Liabilities was $117000.0 for Q3 2025 at Avalo Therapeutics, down from $10.3 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $11.8 million in Q3 2024 and bottomed at $117000.0 in Q3 2025.
  • Average Other Non-Current Liabilities over 5 years is $3.4 million, with a median of $1.9 million recorded in 2022.
  • The sharpest move saw Other Non-Current Liabilities skyrocketed 248.07% in 2024, then tumbled 99.01% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $2.3 million in 2021, then decreased by 25.54% to $1.7 million in 2022, then soared by 224.37% to $5.6 million in 2023, then tumbled by 93.69% to $350000.0 in 2024, then plummeted by 66.57% to $117000.0 in 2025.
  • Business Quant data shows Other Non-Current Liabilities for AVTX at $117000.0 in Q3 2025, $10.3 million in Q2 2025, and $275000.0 in Q1 2025.